Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)

NCT04527575 is registered in ClinicalTrials.gov with Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" as lead sponsor.

NCT NCT04527575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04527575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)
Lead sponsor
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Phase
Phase 1/2
Overall status
Completed
Start date
July 27, 2020
Completion date
December 30, 2021
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19